Loading
A phase 3 trial of Odronextamab, Rituximab, Cyclophosphamide in follicular lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT06097364 by Regeneron Pharmaceuticals, with 733 participants planned, started 2023-11-14 and due to reach its primary completion in 2029-07-29. Interventions recorded: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
Shares Odronextamab, Regeneron, Prednisone, Vincristine.
Shares Odronextamab, Regeneron, Prednisone, Vincristine.
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, Follicular lymphoma.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Shares Prednisone, Vincristine, Rituximab, Doxorubicin.